Toshifumi Tada1, Takashi Kumada1, Hidenori Toyoda1, Kunihiko Tsuji2, Atsushi Hiraoka3, Kojiro Michitaka3, Akihiro Deguchi4, Toru Ishikawa5, Michitaka Imai5, Hironori Ochi6, Koji Joko6, Noritomo Shimada7, Kazuto Tajiri8, Masashi Hirooka9, Yohei Koizumi9, Yoichi Hiasa9, Junko Tanaka10. 1. Department of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan. 2. Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan. 3. Gastroenterology Center, Ehime Prefectural Central Hospital, Matsuyama, Japan. 4. Department of Gastroenterology, Kagawa-Rosai Hospital, Marugame, Japan. 5. Department of Gastroenterology, Saiseikai Niigata Daini Hospital, Niigata, Japan. 6. Hepato-Biliary Center, Matsuyama Red-Cross Hospital, Matsuyama, Japan. 7. Department of Gastroenterology, Otakanomori Hospital, Kashiwa, Japan. 8. Department of Gastroenterology, Toyama University Hospital, Toyama, Japan. 9. Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Matsuyama, Japan. 10. Department of Epidemiology, Infectious Disease Control, and Prevention, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.
Abstract
BACKGROUND AND AIM: Albumin-bilirubin (ALBI) grade was developed as a new method to assess hepatic function. Sorafenib has been confirmed to be effective in improving survival in patients with advanced hepatocellular carcinoma (HCC). In this study, we investigated the impact of ALBI grade versus Child-Pugh classification on survival in HCC patients who received sorafenib. METHODS: A total of 567 patients with advanced HCC who received sorafenib were included. We analyzed survival based on Child-Pugh classification or score and ALBI grade or score. We also compared the ability of ALBI and Child-Pugh scores to predict survival using time-dependent receiver operating characteristic analysis. RESULTS: Cumulative survival rates at 90, 180, 360, and 720 days were 84.1%, 66.6%, 47.0%, and 23.3%, respectively. Median survival was 316 days (95% confidence interval, 279-377). Both Child-Pugh classification and ALBI grade were independently associated with overall survival in multivariate analyses. In addition, overall survival differed significantly between patients with ALBI grades 1 and 2 (hazard ratio, 1.44; 95% confidence interval, 1.09-1.92, P = 0.011) among patients with a Child-Pugh score of 5. Time-dependent receiver operating characteristic analysis showed that ALBI score predicted overall survival better than Child-Pugh score. CONCLUSIONS: Albumin-bilirubin grade is a better predictor of survival in patients with advanced HCC who received sorafenib therapy than Child-Pugh classification.
BACKGROUND AND AIM: Albumin-bilirubin (ALBI) grade was developed as a new method to assess hepatic function. Sorafenib has been confirmed to be effective in improving survival in patients with advanced hepatocellular carcinoma (HCC). In this study, we investigated the impact of ALBI grade versus Child-Pugh classification on survival in HCC patients who received sorafenib. METHODS: A total of 567 patients with advanced HCC who received sorafenib were included. We analyzed survival based on Child-Pugh classification or score and ALBI grade or score. We also compared the ability of ALBI and Child-Pugh scores to predict survival using time-dependent receiver operating characteristic analysis. RESULTS: Cumulative survival rates at 90, 180, 360, and 720 days were 84.1%, 66.6%, 47.0%, and 23.3%, respectively. Median survival was 316 days (95% confidence interval, 279-377). Both Child-Pugh classification and ALBI grade were independently associated with overall survival in multivariate analyses. In addition, overall survival differed significantly between patients with ALBI grades 1 and 2 (hazard ratio, 1.44; 95% confidence interval, 1.09-1.92, P = 0.011) among patients with a Child-Pugh score of 5. Time-dependent receiver operating characteristic analysis showed that ALBI score predicted overall survival better than Child-Pugh score. CONCLUSIONS: Albumin-bilirubin grade is a better predictor of survival in patients with advanced HCC who received sorafenib therapy than Child-Pugh classification.
Authors: Thi Thu Huong Nguyen; Van Hieu Nguyen; Van Hung Nguyen; Thanh Long Nguyen; Van Quang Le Journal: Cancer Control Date: 2019 Jan-Dec Impact factor: 3.302
Authors: Tim A Labeur; Sarah Berhane; Julien Edeline; Jean-Frederic Blanc; Dominik Bettinger; Tim Meyer; Jeroen L A Van Vugt; David W G Ten Cate; Robert A De Man; Ferry A L M Eskens; Alessandro Cucchetti; Laura J Bonnett; Otto M Van Delden; Heinz-Josef Klümpen; R Bart Takkenberg; Philip J Johnson Journal: Liver Int Date: 2019-11-18 Impact factor: 5.828